Korea's First FDA-NDA Win Changes the Game for Biliary Tract Cancer

The Record That Nobody Will Stop Talking About

HLB’s FGFR2 inhibitor lirafugratinib—sold under the brand name Lyrfigtu—has received US FDA approval as a second-line treatment for FGFR2 fusion and rearrangement-positive advanced or metastatic cholangiocarcinoma. The more consequential detail, one that will reverberate through Seoul’s biotech corridors for years: this is the first time a Korean pharmaceutical or biotech company has independently filed its own New Drug Application at the FDA and had it approved.

The milestone matters because the old playbook required Korean developers to outsource NDA filings to partners with US regulatory experience. That dynamic is now officially broken.

What the Data Actually Shows

The approval rests on the ReFocus global Phase 1/2 trial, which enrolled 116 patients with unresectable or metastatic cholangiocarcinoma who had previously received chemotherapy or immunotherapy but had never been treated with an FGFR inhibitor. All participants received 70mg of lirafugratinib once daily.

The results are competitive, even if not record-breaking:

• Overall response rate: 45.7% (53 of 116 patients)
• Median duration of response: 11.8 months
• Median progression-free survival: 11.3 months
• 12-month PFS rate: 49.2%
• Median overall survival: 22.8 months

For context, median OS of 22.8 months in a second-line setting for this disease is respectable. Biliary tract cancer remains one of the more lethal solid tumors, and historically, patients who progress on first-line platinum-based chemotherapy have very limited options.

The safety profile is where lirafugratinib draws its sharpest contrast. Hyperphosphatemia—a known class-effect of FGFR inhibitors that can cause serious cardiovascular and renal complications—occurred in just 20.7% of patients. Diarrhea, another common FGFR inhibitor toxicity, hit 21.6%. Both rates sit below what previous-generation FGFR inhibitors like pemigatinib and futibatinib have reported.

Dr. Alison Schram of Memorial Sloan Kettering called the data a “new therapeutic possibility” for FGFR2-fusion-positive patients and stressed the importance of molecular testing early in the diagnostic pathway. That last point is the practical takeaway for clinicians: Lyrfigtu is effective only in a molecularly selected population, and that population is currently under-identified.

The Selectivity Thesis

Lirafugratinib was engineered for selectivity. It binds preferentially to FGFR2 while minimizing off-target inhibition of FGFR1, FGFR3, and FGFR4. The clinical signal—that hyperphosphatemia and diarrhea rates are lower than class peers—is consistent with that design intent. FGFR1 and FGFR4 inhibition is the primary driver of phosphate dysregulation; reducing exposure there should translate into fewer metabolic adverse events.

Whether that selectivity advantage is large enough to sway prescribing habits against established competitors remains an open question. But the mechanism is sound, and the data so far supports it.

The Asset Chain: How HLB Got Here

Lyrfigtu did not originate at HLB. Elevar Therapeutics, HLB’s US subsidiary, acquired the asset from Relay Therapeutics in 2024 for a total deal value of $500 million. Relay, founded by Andrew Fraser and backed by Andreessen Horowitz, had been developing lirafugratinib as a next-generation FGFR2-selective inhibitor.

Elevar itself is a spin-out from Relay’s former asset portfolio, and HLB’s acquisition of Elevar was part of a broader strategy to build a US-based commercial organization around pipeline assets with global potential. The structural arrangement—Korean parent, US operating subsidiary, US regulatory filing—mirrors the very model that this approval validates as viable.

Who Wins, Who Loses

Relay Therapeutics sold its FGFR2 program at a premium and exited before bearing the commercialization risk. Their returns are locked in.

Elevar and HLB now carry the weight of launch execution in the US market, with Q4 release targeted this year. They also face the task of commercializing in Europe, where a Marketing Authorization Application was submitted to the EMA on the 14th.

Patients with FGFR2-altered cholangiocarcinoma gain a new second-line option with what appears to be a more favorable tolerability profile than existing FGFR inhibitors. If real-world data tracks with the clinical trial, prescribing patterns could shift toward lirafugratinib, especially among patients who previously could not tolerate the phosphate and GI side effects of earlier drugs.

Earlier FGFR inhibitors—pemigatinib (Incyte), futibatinib (Taiho), and ibferotinib (Amgen/BMS)—face a competitive landscape that just got narrower. None of them has demonstrated the selectivity-driven safety advantages that lirafugratinib appears to show, though all three have established prescriber familiarity and insurance network relationships that take time to displace.

Korean biotech companies that have been struggling to get FDA approvals through partnerships now have a reference point. The constraint was never scientific capability—it was regulatory execution. That constraint is removed.

What Comes Next

Elevar is running the ReFocus202 Phase 2 trial to evaluate lirafugratinib in FGFR2-mutant non-CCA solid tumors as a second-line therapy. If that program generates signals, the addressable population expands significantly beyond cholangiocarcinoma.

The European filing adds another timeline to watch. EMA decisions on oncology indications typically run 10–12 months from submission, which would place a potential EU approval sometime in late 2027.

And then there is the broader implication: Korean biotechs will no longer need to prove their science to global partners as the primary gateway to FDA approval. They can file their own NDAs. That shifts the negotiation dynamics for every licensing deal Korea signs going forward.

The question is not whether this model will be replicated. It is which company goes next.